AbCellera Biologics Inc.(ABCL)Earnings Date, History & Expected Move
Next report date, beat rate and options-implied move
ABCL has no upcoming report date in the calendar yet. It last reported on Nov 9, 2026; companies usually report every three months.
EPS: Actual vs Estimate
Reported EPS against the consensus estimate, last 12 quarters.
Green beat or met, red missed, amber sources differ.
Stock Reaction After Earnings
Close-to-close move in the first session that reflected each report.
Dashed lines mark the average actual move (±7.0%).
Did the stock rise after good news?
The next-day move after each of its last 5 EPS beats and 5 misses.
In plain words: it beat expectations 5 times, but the stock still fell 4 of those 5 times.
- Aug '26Missed▲ +10.3%
- May '26Beat▼ -5.7%
- Nov '25Missed▼ -13.7%
- Aug '25Beat▲ +0.2%
- May '25Missed▲ +1.0%
- Feb '25Beat▼ -11.5%
- Nov '24Missed▼ -5.9%
- Aug '24Beat▼ -7.7%
- May '24Beat▼ -5.0%
- Feb '24Missed▼ -9.4%
Clear beats and misses with a known reaction only. What counts as a beat
Why did ABCL fall after beating earnings?
6 of ABCL's last 10 reactions went against the EPS result. What stands out in each:
ABCL beat EPS estimates in 5 quarters, and the stock still closed lower the next day 4 times. In 2 of the 4 where we have price data, the stock had already run up before the report.
- May 11, 2026EPS beat +30.0%stock -5.7% next day
- It had risen 43.4% in the 20 trading sessions before the report, so good news may already have been priced in.
- It opened 9.3% lower as soon as trading resumed.
- Feb 27, 2025EPS beat +20.0%stock -11.5% next day
- It opened 6.8% lower as soon as trading resumed.
- Aug 6, 2024EPS beat +7.1%stock -7.7% next day
- It opened 3.5% lower as soon as trading resumed.
- May 7, 2024EPS beat +12.5%stock -5.0% next day
- It had risen 6.9% in the final week before the report, so good news may already have been priced in.
Rose despite an EPS miss (2 of 5)
- Aug 5, 2026EPS missed -12.5%stock +10.3% next day
- It had already fallen 16.6% in the 20 trading sessions before the report, so weak results may have been expected.
- May 8, 2025EPS missed -7.1%stock +1.0% next day
- It had already fallen 7.4% in the 20 trading sessions before the report, so weak results may have been expected.
- It opened 2.5% higher as soon as trading resumed.
Patterns in estimates and prices, not confirmed causes: how we read them.
Was ABCL's earnings move already priced in?
ABCL's move in the month before each of its last 10 reports, against what it did after.
How the run-up is measured (a move of 5% or more counts as large).
Before vs after each report
Grey: the month before each of the last 10 reports. Green or red: the day after.
Past reports only. How the run-up is measured
Does ABCL hold its opening gap after earnings?
ABCL's opening move after each report and where it closed that day.
In 9 reports ABCL opened at least 1% away from the previous close. It gave back half or more of that gap by the close 4 of 9 times (44%), and fully reversed 1 time. Gaps up faded 2 of 2; gaps down recovered 2 of 7.
- Aug 5, 2026ReversedOpened -2.2%, closed +10.3%
- May 11, 2026HeldOpened -9.3%, closed -5.7%
- Nov 6, 2025HeldOpened -16.1%, closed -13.7%
- Aug 7, 2025FadedOpened +13.7%, closed +0.2%
- May 8, 2025FadedOpened +2.5%, closed +1.0%
- Feb 27, 2025HeldOpened -6.8%, closed -11.5%
- Nov 4, 2024FadedOpened -13.5%, closed -5.9%
- Aug 6, 2024HeldOpened -3.5%, closed -7.7%
What the history says
- It fell after 4 of its 5 EPS beats (80%): beating estimates has not been enough on its own.
ABCL earnings history
Last 12 reported quarters with the stock's reaction.
Swipe sideways to see every column →
| Report date | Time | EPS est. | EPS actual | Surprise | Revenue surprise | 1-day move | 3-day move |
|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | After close | -$0.18 | -$0.13 | +27.8% | +23.9% | — | — |
| Aug 5, 2026 | After close | -$0.16 | -$0.18 | -12.5% | — | +10.30% | +57.77% |
| May 11, 2026 | After close | -$0.20 | -$0.14 | +30.0% | — | -5.71% | -16.19% |
| Feb 24, 2026 | After close | -$0.18 | -$0.03 | +83.3% | — | — | — |
| Nov 6, 2025 | After close | -$0.16 | -$0.19 | -18.8% | — | -13.69% | -11.48% |
| Aug 7, 2025 | After close | -$0.16 | -$0.12 | +25.0% | — | +0.24% | +0.71% |
| May 8, 2025 | After close | -$0.14 | -$0.15 | -7.1% | — | +1.00% | +4.48% |
| Feb 27, 2025 | After close | -$0.15 | -$0.12 | +20.0% | — | -11.47% | -19.86% |
| Nov 4, 2024 | After close | -$0.13 | -$0.17 | -30.8% | — | -5.88% | -5.88% |
| Aug 6, 2024 | After close | -$0.14 | -$0.13 | +7.1% | — | -7.72% | -5.96% |
| May 7, 2024 | After close | -$0.16 | -$0.14 | +12.5% | — | -4.95% | -5.20% |
| Feb 20, 2024 | After close | -$0.12 | -$0.16 | -33.3% | — | -9.42% | -8.29% |
ABCL Earnings FAQ
Answers computed from AbCellera Biologics Inc.'s reported history
ABCL has no upcoming report date in the calendar yet. It last reported on Nov 9, 2026; companies usually report every three months.
Over the last 12 quarters with a usable EPS surprise, ABCL beat the consensus estimate 7 times (58%), missed 5 and landed in line 0.
Across its last 10 quarters with a measured reaction, ABCL moved an average of ±7.0% in the first session after reporting. It closed higher 30% of the time; the largest gain was 10.3% and the largest drop -13.7%.
ABCL fell in the first session after 4 of its last 5 EPS beats (80%). A beat that was already priced in, or weaker guidance, can send a stock lower. In 2 of the 4 of those falls where price data is available, the stock had already risen before the report.
Across its last 10 quarters with price data, ABCL moved an average of -2.0% in the 20 trading sessions before reporting and was higher in 30% of them. After a drop of 3% or more (6 quarters), it rose the next day 33% of the time, averaging -4.7%. This describes past reports; it is not a forecast.
In 9 reports ABCL opened at least 1% away from the previous close. It gave back half or more of that gap by the close 4 of 9 times (44%), and fully reversed once. A fade means the opening move was partly undone during the first session.
How we calculate these numbers · ABCL: 12 reported quarters, latest Nov 9, 2026. Information only, not investment advice.
Looking for more on ABCL?
Price charts, forecast, fundamentals and risk pages for ABCL are not on Tickzen yet. You can run a full stock analysis now.
Run the ABCL Stock AnalyzerLatest TickZen Insights
AbbVie (ABBV) Q3 2026 Earnings Preview: Will Skyrizi and Rinvoq be able to justify the 20x?By Vishal Jadaun
Alphabet (GOOG) Q3 2026 Earnings Preview: Will Cloud Overtake Capex?By Vishal Jadaun
HSBC Q3 2026 Earnings Preview: Is the $46bn NII Guide Too Low?By Vishal Jadaun